Vendor Intelligence Report: NovaPeptide

Published 2 Jul 2026. 18-page investigative report on who is behind NovaPeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, NovaPeptide shows 4 pass / 0 fail — an overall pass rate of 100%. The useful read is narrow: every result is Retatrutide, making NovaPeptide a reasonable short-record option for that peptide only, not a proxy for the rest of its catalog. Ratings also shift under stricter Finnrick scoring, so the appendix matters.

The identity trail is less tidy. One NovaPeptide sister domain markets a China-based raw-material manufacturer with high-capacity clean-workshop claims; another presents NovaPeptide Inc. as a U.S. biotech at a Wilmington address. The report compares those pages against WHOIS records, a Delaware corporate-registry search, and address checks that do not line up cleanly with the U.S. presentation.

Operational risk is concentrated in buyer recourse and source authentication, not in Retatrutide identity failures. The vendor emphasizes crypto and Western Union-style payment rails alongside WhatsApp and Outlook-style communication; its own Reddit channel also warns about Telegram impersonators, while similarly named coupon and community pages point to other domains. For NovaPeptide, channel verification is as important as vial testing.

Inside the full report:

  • Finnrick rating overview, spark grid, methodology-divergence chart, and Appendix A lab data for Retatrutide
  • Side-by-side comparison of the China-manufacturer homepage and U.S. biotechnology-company sister homepage
  • WHOIS and ScamAdviser exhibit tying the investigated domain to an individual registrant, location, and free-email contact
  • Delaware entity-search and Wilmington virtual-office address analysis
  • Payment and communication recourse review covering crypto, wire, PayPal, WhatsApp, and Outlook
  • Reddit fraud-alert exhibit and promotion scan separating official activity, organic mentions, and similarly named coupon pages

Risk assessment

  • False or unverifiable corporate-identity risk — high: novapeptide.net claims U.S. NovaPeptide Inc. at a Wilmington virtual-office address, but Delaware search returned no such entity; WHOIS/domain evidence points to Chen Mu in Weifang, China.
  • Irreversible-payment and informal-channel risk — high: NovaPeptide advertises BTC, USDT, Western Union, wire and PayPal while routing buyers through WhatsApp/Outlook, materially reducing recourse when anything goes wrong.
  • Copycat and brand-confusion risk — medium: The official subreddit warns of Telegram Novo Peptide scammers, and the promotion scan found similarly named Nova Peptides coupon/community pages for other domains; public verification controls are incomplete.
  • Untested-catalog quality risk — medium: Finnrick data supports Retatrutide only (4 pass / 0 fail; 83.2%); all NovaPeptide products outside Retatrutide lack Finnrick coverage in the supplied record.
  • Unverified manufacturing-claim risk — medium: Claims of 800 kg annual capacity, a Class 10,000 clean workshop, 8 invention patents and Lancet-linked standards were not corroborated by facility, patent or certification records.